The vispa-cel 2L LBCL data (82% ORR, 17.1-month mPFS) strengthen the case for the pivotal ANTLER-3 phase 3 trial, which targets an underserved patient population. The CB-011 MM data (83% CR, early signal in BCMA-exposed patient) de-risks the dose expansion readout expected in H2 2026. Monitor for initial CB-011 dose expansion data in BCMA-naïve and -exposed patients in late 2026, which will be the next meaningful catalyst. Cash runway and ability to fully fund ANTLER-3 remain key risks not addressed in this filing.
CRBU drugs
CRBU drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 11 $1.66entry
- T+1 · 5mo ago −3.92%α −4.46% · $1.60
- T+5 · 5mo ago −1.20%α −1.64% · $1.64
- T+20 · 4mo ago +16.87%α +14.98% · $1.94
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 (vispa-cel, anti-CD19) and CaMMouflage phase 1 (CB-011, anti-BCMA) trials at the EHA 2026 meeting. For vispa-cel in 2L LBCL (pivotal subgroup, N=27): 82% ORR, 67% CR, 17.1-month mPFS. For CB-011 in r/r MM (BCMA-naïve RDE cohort, N=12): 92% ORR, 83% CR, 91% MRD negativity. Both assets showed manageable safety profiles. The company also reiterated FDA alignment on the design of the ANTLER-3 pivotal phase 3 trial for vispa-cel. This data update is a notable but incremental catalyst for this pre-revenue clinical-stage biotech, positive efficacy readouts but from small, single-arm cohorts without financial guidance.
Key Facts
- Vispa-cel in 2L LBCL (pivotal optimized subgroup, N=27): 82% ORR, 67% CR rate, 17.1-month median PFS
- CB-011 in BCMA-naïve r/r MM at RDE (N=12): 92% ORR, 83% CR rate, 91% MRD negativity in 10/11 evaluable, 50% in CR at 15 months
- CB-011 case study: 71-yo male with 8 prior lines (including autologous CAR-T) achieved CR at day 28, ongoing
- No GvHD or Gr≥3 ICANS in both pivotal optimized vispa-cel subgroup (N=27) and CB-011 RDE cohort (N=12)
- FDA alignment reached on ANTLER-3 phase 3 design (~250 patients, 2L LBCL not eligible for transplant/auto-CAR-T, PFS primary endpoint)
- Initial dose expansion data for CB-011 in BCMA-naïve and -exposed patients expected H2 2026
Financial Impact
No revenue; company is pre-commercial. Data update supports pipeline valuation for vispa-cel and CB-011, two allogeneic CAR-T candidates with FDA RMAT, Fast Track, and Orphan Drug designations.
Risk Factors
- Company has a history of net operating losses and needs additional capital to fund operations and the ANTLER-3 phase 3 trial
- Phase 1 data from small single-arm cohorts may not be predictive of phase 3 outcomes or regulatory approval
- Two treatment-related deaths reported across both trials (one vispa-cel-related IEC-HS, one CB-011-related hematotoxicity)
- Pre-revenue biotech with high cash burn and dilutive financing risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001619856-26-000043 |
| Document: crbu-20260611xexx992.htm | 0001619856-26-000043 |
| Document: crbu-20260611xexx991.htm | 0001619856-26-000043 |
| Document: 0001619856-26-000043-index-headers.html | 0001619856-26-000043 |
| Document: 0001619856-26-000043-index.html | 0001619856-26-000043 |
| Document: 0001619856-26-000043.txt | 0001619856-26-000043 |
Track record
13 reports on CRBU
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
- Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
- Jun 11, 202622w ago 8-K Bullish 6/10 Viewing Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
- Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers